Announcements Trials
Browse Landscape

Phase

Phase 1/2 2

Status

Terminated 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 2

Conditions

Neoplasms 2Fallopian Tube Neoplasms 2Carcinoma, Ovarian Epithelial 2Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1Sarcoma 1Pancreatic Neoplasms 1Neoplasm Metastasis 1Melanoma 1Disorders of Sex Development 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Paclitaxel 18Carboplatin 14Topotecan 8liposomal doxorubicin 6Cyclophosphamide 5Cisplatin 5Gemcitabine 4Docetaxel 4oregovomab 3Immunoenzyme Techniques 3Etoposide 3Capecitabine 3pembrolizumab 2fludarabine phosphate 2aldesleukin 2Taxes 2Surgical Procedures, Operative 2Stem Cell Transplantation 2STA 9090 2Peripheral Blood Stem Cell Transplantation 2Oxaliplatin 2Nivolumab 2Microarray Analysis 2Magnetic Resonance Spectroscopy 2Lenalidomide 2Fulvestrant 2Fluorodeoxyglucose F18 2Flow Cytometry 2Filgrastim 2Cytoreduction Surgical Procedures 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × Carcinoma, Ovarian Epithelial × STA 9090 × Clear all
NCT01962948 2024-03-26

Paclitaxel and Ganetespib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Fox Chase Cancer Center

Phase 1/2 Terminated
12 enrolled 8 charts
Gynecologic

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms

NCT02012192 2019-08-13

GANNET53: Ganetespib in Metastatic, p53-mutant, Platinum-resistant Ovarian Cancer

Medical University Innsbruck

Phase 1/2 Terminated
133 enrolled 10 charts
Gynecologic

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Disorders of Sex Development

Data powered by HemOnc (CC BY 4.0) Colophon âš¡